Psychotropic Drug–Related Weight Gain and Its Treatment
American Journal of Psychiatry · 01.01.2024 · 181 (1) · 26-38
DOI: 10.1176/appi.ajp.20230922 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Psychiatry, erschienen am 01.01.2024. Verfasst von Roger S McIntyre und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry (McIntyre, Rosenblat, Mansur) and Department of Pharmacology and Toxicology (McIntyre, Rosenblat, Mansur), University of Tor…. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 118-mal zitiert (Crossref) und nennt 214 Literaturangaben.
Abstract (Originalsprache)
Psychotropic drug-related weight gain (PDWG) is a common occurrence and is highly associated with non-initiation, discontinuation, and dissatisfaction with psychiatric drugs. Moreover, PDWG intersects with the elevated risk for obesity and associated morbidity that has been amply reported in the psychiatric population. Evidence indicates that differential liability for PDWG exists for antipsychotics, antidepressants, and anticonvulsants. During the past two decades, agents within these classes have become available with significantly lower or no liability for PDWG and as such should be prioritized. Although lithium is associated with weight gain, the overall extent of weight gain is significantly lower than previously estimated. The benefit of lifestyle and behavioral modification for obesity and/or PDWG in psychiatric populations is established, with effectiveness similar to that in the general population. Metformin is the most studied pharmacological treatment in the prevention and treatment of PDWG, and promising data are emerging for glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide, exenatide, semaglutide). Most pharmacologic antidotes for PDWG are supported with low-confidence data (e.g., topiramate, histamine-2 receptor antagonists). Future vistas for pharmacologic treatment for PDWG include large, adequately controlled studies with GLP-1 receptor agonists and possibly GLP-1/glucose-dependent insulinotropic polypeptide co-agonists (e.g., tirzepatide) as well as specific dietary modifications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry (McIntyre, Rosenblat, Mansur) and Department of Pharmacology and Toxicology (McIntyre, Rosenblat, Mansur), University of Toronto, Toronto; Brain and Cognition Discovery Foundation, Toronto (McIn…
Zitieren
APA
McIntyre, R. S., Kwan, A. T. H., Rosenblat, J. D., Teopiz, K. M., & Mansur, R. B. (2024). Psychotropic Drug–Related Weight Gain and Its Treatment. American Journal of Psychiatry, 181(1), 26-38. https://doi.org/10.1176/appi.ajp.20230922
Vancouver
McIntyre RS, Kwan ATH, Rosenblat JD, Teopiz KM, Mansur RB. Psychotropic Drug–Related Weight Gain and Its Treatment. American Journal of Psychiatry. 2024;181(1):26-38. doi:10.1176/appi.ajp.20230922
BibTeX
@article{McIntyre2024,
author = {McIntyre, Roger S and Kwan, Angela T H and Rosenblat, Joshua D and Teopiz, Kayla M and Mansur, Rodrigo B},
title = {Psychotropic Drug–Related Weight Gain and Its Treatment},
journal = {American Journal of Psychiatry},
year = {2024},
volume = {181},
number = {1},
pages = {26--38},
doi = {10.1176/appi.ajp.20230922}
}
EUVIMED